Novavax, Inc. (NVAX) Financial Analysis & Valuation | Quarter Chart
Novavax, Inc. (NVAX)
NVAXPrice: $8.12
Fair Value: 🔒
🔒score
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials... more
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization... more
Description
Shares
| Market Cap | $1.32B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | John Charles Jacobs |
| IPO Date | 1995-12-05 | CAGR | 0.38% |
| Employees | 952 | Website | www.novavax.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | -0.15% | Total Yield | -0.15% |
NVAX chart loading...
Fundamentals
Technicals
| Enterprise Value | $784.24M | P/E Ratio | 3.1 |
| Forward P/E | -8.01 | PEG Ratio | — |
| P/S Ratio | 0.11 | P/B Ratio | -0.96 |
| P/CF Ratio | -0.49 | P/FCF Ratio | -0.48 |
| EPS | $2.62 | EPS Growth 1Y | -293.98% |
| EPS Growth 3Y | -130.57% | EPS Growth 5Y | -138% |
| Revenue Growth 1Y | 64.69% | Gross Margin | 0.93% |
| Operating Margin | 0.4% | Profit Margin | 0.39% |
| ROE | -5.46% | ROA | 0.37% |
| ROCE | 0.63% | Current Ratio | 2.13 |
| Quick Ratio | 2.1 | Cash Ratio | 0.52 |
| Debt/Equity | -1.95 | Interest Coverage | -20.08 |
| Altman Z Score | -1.99 | Piotroski Score | 5 |